Solventum Announces Pricing of Secondary Offering of Common Stock

Core Viewpoint - Solventum Corporation announced a secondary offering of 8,800,000 shares of its common stock, expected to generate approximately $648 million in gross proceeds for 3M Company, the selling shareholder, with the offering closing around August 15, 2025 [1]. Group 1: Offering Details - The offering consists of shares sold entirely by the selling shareholder, 3M Company, and Solventum will not receive any proceeds from this offering [1]. - Goldman Sachs & Co. LLC and BofA Securities are acting as underwriters for the offering [2]. - The shares are being offered under the Company's shelf registration statement on Form S-3, which became effective upon filing with the SEC on August 13, 2025 [3]. Group 2: Regulatory Information - The offering is made only by means of a preliminary prospectus supplement filed with the SEC, and interested parties can access these documents for more information [3]. - The press release clarifies that it does not constitute an offer to sell or solicit an offer to buy the securities in any jurisdiction where such actions would be unlawful [4]. Group 3: Company Overview - Solventum aims to enhance healthcare through innovative solutions at the intersection of health, material, and data science, focusing on improving patient outcomes and empowering healthcare professionals [7].